SOLV Stock: Price, Earnings History and SEC Filings
Solventum Corporation (SOLV) last traded at $81.33, down 2.67% on the latest session and down 7.7% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $2.55 against an analyst estimate of $1.91, a beat of 33.5%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
SOLV earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $2.55 | $1.91 | +33.51% |
| Mar 2026 | May 5, 2026 | $1.48 | $1.35 | +9.63% |
| Dec 2025 | Feb 26, 2026 | $1.57 | $1.50 | +4.67% |
| Sep 2025 | Nov 6, 2025 | $1.50 | $1.43 | +4.90% |
SOLV beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
How SOLV reacts to earnings
Across its last 8 earnings releases, SOLV moved 4.3% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-05 | After close | -5.16% |
| 2026-05-05 | After close | +2.82% |
| 2026-02-26 | After close | -3.56% |
| 2025-11-06 | After close | +7.91% |
| 2025-08-07 | After close | +2.00% |
| 2025-05-08 | After close | +5.40% |
| 2025-02-27 | After close | -4.42% |
| 2024-11-07 | After close | -3.52% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
SOLV financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $8.3B | $1.6B | -$10M | 18.7% | $8.88 |
| 2024 | $8.3B | $479M | $805M | 5.8% | $2.76 |
| 2023 | $8.2B | $1.3B | $1.6B | 16.4% | $7.79 |
| 2022 | $8.1B | $1.3B | $1.4B | 16.5% | $7.78 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for SOLV
- 10-Q · Aug 5, 2026
- 8-K · Aug 5, 2026Results of operations, Financial statements and exhibits
- 8-K · Aug 5, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 8-K · Jul 20, 2026Officer or director change
- 8-K · Jun 5, 2026Other events, Financial statements and exhibits
- 8-K · May 27, 2026Officer or director change, Financial statements and exhibits
- 8-K · May 20, 2026Shareholder vote
- 10-Q · May 5, 2026
- 8-K · May 5, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Mar 27, 2026
Insider filing activity
SOLV insiders filed 2 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
SOLV news
- Solventum Corp.Oct 31, 2026 · 247wallst.com
- Solventum (SOLV) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseOct 29, 2026 · finance.yahoo.com
- Should Steris Stock Holders Look At Medtronic Instead?Oct 29, 2026 · trefis.com
- Here's why Solventum (SOLV) is a strong value stockOct 29, 2026 · msn.com
- Solventum’s Quarterly Earnings Preview: What You Need to KnowOct 27, 2026 · barchart.com
- 2 cash-burning stocks for long-term investors and 1 we turn downOct 23, 2026 · finance.yahoo.com
- SOLV Wins FDA Clearance to Combine Restrata Matrix With V.A.C.TherapyOct 23, 2026 · finance.yahoo.com
- Mexico Prefabricated Crown and Bridge Materials Market Outlook to 2036: Permanent Crowns and Bridges Revenue, Volume and PricingOct 22, 2026 · finance.yahoo.com
About Solventum Corporation
Solventum Corporation (SOLV) is a US-listed public company on NYSE. The SEC classifies its business as Surgical & Medical Instruments & Apparatus. It is incorporated in DE. Its fiscal year ends in December.